bioAffinity Technologies, Inc. (BIAF)

US — Healthcare Sector
Peers: IDXG  INBS  SQL  BIOC    TTOO  GENE  HTGM  GTH  PMD  PRPO 

Automate Your Wheel Strategy on BIAF

With Tiblio's Option Bot, you can configure your own wheel strategy including BIAF - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BIAF
  • Rev/Share 0.5419
  • Book/Share 0.0885
  • PB 2.9671
  • Debt/Equity 0.9248
  • CurrentRatio 0.5457
  • ROIC -3.4754

 

  • MktCap 7345070.0
  • FreeCF/Share -0.409
  • PFCF -1.1047
  • PE -0.4386
  • Debt/Assets 0.24
  • DivYield 0
  • ROE -3.6764

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
BIAF
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Negative

bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.

Read More
image for news BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
BIAF
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral

JERSEY CITY, N.J. , May 7, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by the company.

Read More
image for news WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
bioAffinity Technologies Announces Closing of $3.25 Million Offering
BIAF
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today closed the previously announced best efforts offering of securities for aggregate gross proceeds of $3.25 million.

Read More
image for news bioAffinity Technologies Announces Closing of $3.25 Million Offering
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
BIAF
Published: April 17, 2025 by: Business Wire
Sentiment: Neutral

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs.

Read More
image for news bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
BIAF
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive

bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.

Read More
image for news BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
BIAF
Published: February 25, 2025 by: Business Wire
Sentiment: Neutral

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity has entered into warrant exercise agreements to exercise certain outstanding warrants for gross cash proceeds of $1.4 million.

Read More
image for news bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

About bioAffinity Technologies, Inc. (BIAF)

  • IPO Date 2022-09-01
  • Website https://www.bioaffinitytech.com
  • Industry Medical - Diagnostics & Research
  • CEO Ms. Maria Zannes J.D.
  • Employees 57

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.